CN103919781A - 用于腹主动脉瘤治疗的三唑并[4, 5-d]嘧啶化合物 - Google Patents
用于腹主动脉瘤治疗的三唑并[4, 5-d]嘧啶化合物 Download PDFInfo
- Publication number
- CN103919781A CN103919781A CN201410139401.5A CN201410139401A CN103919781A CN 103919781 A CN103919781 A CN 103919781A CN 201410139401 A CN201410139401 A CN 201410139401A CN 103919781 A CN103919781 A CN 103919781A
- Authority
- CN
- China
- Prior art keywords
- compound
- treatment
- day
- difluorophenyl
- thrombosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000002223 abdominal aortic aneurysm Diseases 0.000 title claims abstract description 22
- GIIGHSIIKVOWKZ-UHFFFAOYSA-N 2h-triazolo[4,5-d]pyrimidine Chemical class N1=CN=CC2=NNN=C21 GIIGHSIIKVOWKZ-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 74
- 230000002265 prevention Effects 0.000 claims abstract description 13
- 208000007474 aortic aneurysm Diseases 0.000 claims description 16
- -1 3,4-difluorophenyl Chemical group 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 5
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 claims description 3
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 230000003287 optical effect Effects 0.000 claims 1
- 239000002464 receptor antagonist Substances 0.000 abstract description 3
- 102100037600 P2Y purinoceptor 1 Human genes 0.000 abstract 1
- 108050008996 P2Y purinoceptor 1 Proteins 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 description 55
- 206010002329 Aneurysm Diseases 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 13
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 13
- 210000000224 granular leucocyte Anatomy 0.000 description 12
- 210000002540 macrophage Anatomy 0.000 description 12
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 12
- 241000053227 Themus Species 0.000 description 11
- 210000000709 aorta Anatomy 0.000 description 10
- 238000004043 dyeing Methods 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 230000008595 infiltration Effects 0.000 description 7
- 238000001764 infiltration Methods 0.000 description 7
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 210000004177 elastic tissue Anatomy 0.000 description 5
- 238000012744 immunostaining Methods 0.000 description 5
- QWENRTYMTSOGBR-UHFFFAOYSA-N 1H-1,2,3-Triazole Chemical compound C=1C=NNN=1 QWENRTYMTSOGBR-UHFFFAOYSA-N 0.000 description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
- YIQKLZYTHXTDDT-UHFFFAOYSA-H Sirius red F3B Chemical compound C1=CC(=CC=C1N=NC2=CC(=C(C=C2)N=NC3=C(C=C4C=C(C=CC4=C3[O-])NC(=O)NC5=CC6=CC(=C(C(=C6C=C5)[O-])N=NC7=C(C=C(C=C7)N=NC8=CC=C(C=C8)S(=O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)O)S(=O)(=O)O)S(=O)(=O)[O-])S(=O)(=O)[O-].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+] YIQKLZYTHXTDDT-UHFFFAOYSA-H 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000010118 platelet activation Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 3
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000002776 aggregation Effects 0.000 description 3
- 238000004220 aggregation Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229920001436 collagen Polymers 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000011694 lewis rat Methods 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002991 immunohistochemical analysis Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- QFIIYGZAUXVPSZ-UHFFFAOYSA-N 8-(2,4-dihydroxy-6-methylanilino)-2-(2,4-dihydroxy-6-methylphenyl)imino-7-hydroxy-1,9-dimethyldibenzofuran-3-one Chemical compound CC1=CC(=CC(=C1NC2=C(C3=C(C=C2O)OC4=CC(=O)C(=NC5=C(C=C(C=C5C)O)O)C(=C43)C)C)O)O QFIIYGZAUXVPSZ-UHFFFAOYSA-N 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 108010059108 CD18 Antigens Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000004218 Orcein Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000007214 atherothrombosis Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 229950008138 carmellose Drugs 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013427 histology analysis Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 210000002570 interstitial cell Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000007474 nonparametric Mann- Whitney U test Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 235000019248 orcein Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 238000004879 turbidimetry Methods 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07301616.4 | 2007-12-03 | ||
| EP07301616 | 2007-12-03 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008801189070A Division CN101883565A (zh) | 2007-12-03 | 2008-12-02 | 用于腹主动脉瘤治疗的三唑并[4，5-d]嘧啶化合物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103919781A true CN103919781A (zh) | 2014-07-16 |
Family
ID=40717966
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410139401.5A Pending CN103919781A (zh) | 2007-12-03 | 2008-12-02 | 用于腹主动脉瘤治疗的三唑并[4, 5-d]嘧啶化合物 |
| CN2008801189070A Pending CN101883565A (zh) | 2007-12-03 | 2008-12-02 | 用于腹主动脉瘤治疗的三唑并[4，5-d]嘧啶化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008801189070A Pending CN101883565A (zh) | 2007-12-03 | 2008-12-02 | 用于腹主动脉瘤治疗的三唑并[4，5-d]嘧啶化合物 |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20100298350A1 (https=) |
| EP (1) | EP2229172B1 (https=) |
| JP (1) | JP5701060B2 (https=) |
| KR (1) | KR101563757B1 (https=) |
| CN (2) | CN103919781A (https=) |
| AU (1) | AU2008331984B2 (https=) |
| BR (1) | BRPI0819458A2 (https=) |
| CA (1) | CA2707488C (https=) |
| CY (1) | CY1115760T1 (https=) |
| DK (1) | DK2229172T3 (https=) |
| EA (1) | EA201000928A1 (https=) |
| ES (1) | ES2522317T3 (https=) |
| HR (1) | HRP20141081T1 (https=) |
| IL (1) | IL205613A (https=) |
| MX (1) | MX2010006101A (https=) |
| MY (1) | MY159656A (https=) |
| NZ (1) | NZ585513A (https=) |
| PL (1) | PL2229172T3 (https=) |
| PT (1) | PT2229172E (https=) |
| RS (1) | RS53635B1 (https=) |
| SI (1) | SI2229172T1 (https=) |
| UA (1) | UA100864C2 (https=) |
| WO (1) | WO2009072967A1 (https=) |
| ZA (1) | ZA201003599B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102653539B (zh) * | 2011-03-01 | 2014-09-17 | 秦引林 | 一种抗血小板聚集化合物及其药物组合 |
| CN102924457A (zh) * | 2011-08-12 | 2013-02-13 | 上海恒瑞医药有限公司 | 三唑并嘧啶类衍生物、其制备方法及其用途 |
| WO2013033178A1 (en) | 2011-08-30 | 2013-03-07 | University Of Utah Research Foundation | Methods and compositions for treating nephrogenic diabetes insipidus |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334816A (zh) * | 1998-12-04 | 2002-02-06 | 阿斯特拉曾尼卡有限公司 | 新的三唑并(4,5－d)嘧啶化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TR199800019T1 (xx) * | 1995-07-11 | 1998-05-21 | Astra Pharmaceuticals Limited | Trombosit topaklanmas�n� �nleyici yeni maddeler. |
| AR017014A1 (es) * | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos |
| GB0013407D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
| SE0101932D0 (sv) * | 2001-05-31 | 2001-05-31 | Astrazeneca Ab | Pharmaceutical combinations |
| WO2009007675A2 (en) * | 2007-07-11 | 2009-01-15 | Cardoz Ab | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist |
-
2008
- 2008-02-12 UA UAA201005772A patent/UA100864C2/uk unknown
- 2008-12-02 WO PCT/SE2008/051386 patent/WO2009072967A1/en not_active Ceased
- 2008-12-02 PL PL08857354T patent/PL2229172T3/pl unknown
- 2008-12-02 MX MX2010006101A patent/MX2010006101A/es active IP Right Grant
- 2008-12-02 ES ES08857354.8T patent/ES2522317T3/es active Active
- 2008-12-02 SI SI200831311T patent/SI2229172T1/sl unknown
- 2008-12-02 EA EA201000928A patent/EA201000928A1/ru unknown
- 2008-12-02 CN CN201410139401.5A patent/CN103919781A/zh active Pending
- 2008-12-02 AU AU2008331984A patent/AU2008331984B2/en active Active
- 2008-12-02 RS RS20140600A patent/RS53635B1/sr unknown
- 2008-12-02 CN CN2008801189070A patent/CN101883565A/zh active Pending
- 2008-12-02 KR KR1020107013193A patent/KR101563757B1/ko active Active
- 2008-12-02 DK DK08857354.8T patent/DK2229172T3/da active
- 2008-12-02 PT PT88573548T patent/PT2229172E/pt unknown
- 2008-12-02 JP JP2010536888A patent/JP5701060B2/ja active Active
- 2008-12-02 US US12/745,733 patent/US20100298350A1/en not_active Abandoned
- 2008-12-02 NZ NZ585513A patent/NZ585513A/en unknown
- 2008-12-02 BR BRPI0819458 patent/BRPI0819458A2/pt not_active Application Discontinuation
- 2008-12-02 EP EP08857354.8A patent/EP2229172B1/en active Active
- 2008-12-02 CA CA2707488A patent/CA2707488C/en not_active Expired - Fee Related
- 2008-12-02 MY MYPI2010002526A patent/MY159656A/en unknown
- 2008-12-02 HR HRP20141081AT patent/HRP20141081T1/hr unknown
-
2010
- 2010-05-06 IL IL205613A patent/IL205613A/en active IP Right Grant
- 2010-05-20 ZA ZA2010/03599A patent/ZA201003599B/en unknown
-
2014
- 2014-10-30 CY CY20141100893T patent/CY1115760T1/el unknown
-
2015
- 2015-01-15 US US14/597,255 patent/US20150272955A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1334816A (zh) * | 1998-12-04 | 2002-02-06 | 阿斯特拉曾尼卡有限公司 | 新的三唑并(4,5－d)嘧啶化合物 |
Non-Patent Citations (1)
| Title |
|---|
| ZIAD TOUAT等: "Renewal of mural thrombus releases plasma markers and is involved in aortic abdominal aneurysm evolution", 《AMERICAN JOURNAL OF PATHOLOGY》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101563757B1 (ko) | 2015-10-27 |
| EP2229172A4 (en) | 2012-12-26 |
| IL205613A0 (en) | 2010-11-30 |
| MX2010006101A (es) | 2010-10-04 |
| BRPI0819458A2 (pt) | 2015-05-05 |
| JP5701060B2 (ja) | 2015-04-15 |
| NZ585513A (en) | 2012-07-27 |
| EA201000928A1 (ru) | 2010-12-30 |
| ES2522317T3 (es) | 2014-11-14 |
| CY1115760T1 (el) | 2017-01-25 |
| CN101883565A (zh) | 2010-11-10 |
| CA2707488A1 (en) | 2009-06-11 |
| PT2229172E (pt) | 2014-11-03 |
| US20100298350A1 (en) | 2010-11-25 |
| RS53635B1 (sr) | 2015-04-30 |
| DK2229172T3 (da) | 2014-11-10 |
| EP2229172A1 (en) | 2010-09-22 |
| JP2011505417A (ja) | 2011-02-24 |
| HK1148195A1 (en) | 2011-09-02 |
| AU2008331984B2 (en) | 2012-08-16 |
| US20150272955A1 (en) | 2015-10-01 |
| SI2229172T1 (sl) | 2014-12-31 |
| AU2008331984A1 (en) | 2009-06-11 |
| PL2229172T3 (pl) | 2015-01-30 |
| MY159656A (en) | 2017-01-13 |
| IL205613A (en) | 2015-04-30 |
| HRP20141081T1 (hr) | 2015-01-02 |
| WO2009072967A1 (en) | 2009-06-11 |
| EP2229172B1 (en) | 2014-09-10 |
| ZA201003599B (en) | 2012-10-31 |
| KR20100099175A (ko) | 2010-09-10 |
| UA100864C2 (uk) | 2013-02-11 |
| CA2707488C (en) | 2015-07-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xia et al. | Hepatocyte growth factor attenuates liver fibrosis induced by bile duct ligation | |
| Merkulova et al. | Ponatinib treatment promotes arterial thrombosis and hyperactive platelets | |
| MX2011004614A (es) | Metodo para tratar o prevenir la trombosis usando etexilato de dabigatran o una sal del mismo con un perfil de seguridad mejorado sobre la terapia con warfarina convencional. | |
| JPWO2010071164A1 (ja) | 活性化血液凝固第Ｘ因子（ＦＸａ）阻害剤 | |
| TW201031651A (en) | Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy | |
| WO2005008250A1 (en) | Compounds and methods for promoting angiogenesis by using a gamma-secretase inhibitor or inhibiting the gamma-secretase pathway | |
| CN103919781A (zh) | 用于腹主动脉瘤治疗的三唑并[4, 5-d]嘧啶化合物 | |
| Zhao et al. | TPN171H alleviates pulmonary hypertension via inhibiting inflammation in hypoxia and monocrotaline-induced rats | |
| JP6959371B2 (ja) | 純粋な５−ｈｔ６受容体アンタゴニストの新たな使用 | |
| TW202045180A (zh) | 治療纖維化之方法 | |
| JP2007537184A (ja) | 抗血小板剤に対する耐性を治療するためのジピリダモールの使用 | |
| AU2016347881A1 (en) | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor | |
| CN101550135A (zh) | As-605240的制备方法及在制备治疗炎性疾病药物中的应用 | |
| WO2017157248A1 (zh) | 三乙酰基-3-羟基苯基腺苷在制备治疗动脉粥样硬化药物中的应用 | |
| JPWO2011007565A1 (ja) | ＰＰＡＲγ阻害剤を用いる動脈瘤の予防および治療 | |
| CN109806263A (zh) | 一种药物组合物及其制备方法和用途 | |
| CN109602748A (zh) | 维生素b2在制备预防和治疗纤维化疾病药物中的用途 | |
| KR19990087396A (ko) | 재협착 치료 또는 예방용 의약의 제조를 위한 2-(3,4-디메톡시신남오일)아미노벤조산의 사용 | |
| Khosravi et al. | Biological Evaluation of New Oxadiazole-Based Synthetic α-glycosidase Inhibitors for Hyperglycemia Management: A Research Study: New Oxadiazoles act as a-glycosidase inhibitor | |
| HK1148195B (en) | Ticagrelor for treatment of abdominal aortic aneurysms | |
| CN119548498A (zh) | 治疗冠状动脉钙化或心肌缺血或梗死的药物 | |
| CN121512993A (zh) | 藁本内酯在制备减轻心肌缺血后炎症反应的药物中的应用 | |
| Downes et al. | Juvenile toxicity: A study of histological organ development in juvenile rats and correlation with known stage of development in man | |
| Temelkova-Kurktschiev et al. | Microalbuminuria is an independent risk factor for increased intima-media thickness: Data from the riad study | |
| Lane et al. | The Influence of Thromboxane Receptor Blockade on Platelet Uptake in Dacron Grafts in Man |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140716 |
|
| RJ01 | Rejection of invention patent application after publication |